Advisors Asset Management Inc. cut its position in shares of C.R. Bard, Inc. (NYSE:BCR) by 44.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,911 shares of the medical instruments supplier’s stock after selling 5,482 shares during the period. Advisors Asset Management Inc.’s holdings in C.R. Bard were worth $2,215,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its stake in shares of C.R. Bard by 70.4% during the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 460 shares of the medical instruments supplier’s stock worth $145,000 after purchasing an additional 190 shares during the last quarter. Parallel Advisors LLC increased its stake in shares of C.R. Bard by 2.8% during the 2nd quarter. Parallel Advisors LLC now owns 513 shares of the medical instruments supplier’s stock worth $164,000 after purchasing an additional 14 shares during the last quarter. Captrust Financial Advisors acquired a new position in shares of C.R. Bard during the 2nd quarter worth about $192,000. Choate Investment Advisors acquired a new position in shares of C.R. Bard during the 2nd quarter worth about $201,000. Finally, Argyle Capital Management Inc. acquired a new position in shares of C.R. Bard during the 2nd quarter worth about $209,000. Institutional investors own 80.31% of the company’s stock.

A number of research analysts recently commented on BCR shares. Cowen Inc reiterated a “hold” rating and issued a $317.00 price target on shares of C.R. Bard in a research note on Friday, November 3rd. Needham & Company LLC reiterated a “hold” rating on shares of C.R. Bard in a research note on Thursday, October 26th. Jefferies Group LLC reiterated a “hold” rating and issued a $317.00 price target on shares of C.R. Bard in a research note on Thursday, September 14th. Barclays PLC upped their price target on shares of C.R. Bard from $245.00 to $337.00 and gave the company an “equal weight” rating in a research note on Monday, November 6th. Finally, BidaskClub downgraded shares of C.R. Bard from a “hold” rating to a “sell” rating in a report on Saturday, August 5th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and one has issued a strong buy rating to the company’s stock. C.R. Bard has an average rating of “Hold” and an average target price of $303.50.

In related news, VP Betty D. Larson sold 5,906 shares of the company’s stock in a transaction that occurred on Friday, October 20th. The shares were sold at an average price of $330.16, for a total transaction of $1,949,924.96. Following the completion of the transaction, the vice president now directly owns 10,753 shares in the company, valued at approximately $3,550,210.48. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Timothy P. Collins sold 55,818 shares of the company’s stock in a transaction that occurred on Thursday, October 12th. The stock was sold at an average price of $322.03, for a total transaction of $17,975,070.54. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 191,593 shares of company stock valued at $62,655,513. 0.80% of the stock is currently owned by insiders.

Shares of C.R. Bard, Inc. (NYSE:BCR) opened at $336.11 on Monday. C.R. Bard, Inc. has a twelve month low of $206.26 and a twelve month high of $336.98. The company has a current ratio of 1.72, a quick ratio of 1.37 and a debt-to-equity ratio of 0.57. The firm has a market cap of $24,499.73, a P/E ratio of 29.03, a PEG ratio of 2.57 and a beta of 0.53.

C.R. Bard (NYSE:BCR) last issued its quarterly earnings results on Wednesday, October 25th. The medical instruments supplier reported $3.02 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.96 by $0.06. C.R. Bard had a net margin of 14.75% and a return on equity of 48.28%. The company had revenue of $989.80 million during the quarter, compared to the consensus estimate of $990.64 million. During the same quarter in the prior year, the firm posted $2.64 EPS. The firm’s quarterly revenue was up 5.1% on a year-over-year basis. research analysts forecast that C.R. Bard, Inc. will post 11.89 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, December 29th. Stockholders of record on Friday, December 8th will be issued a dividend of $0.26 per share. This represents a $1.04 dividend on an annualized basis and a dividend yield of 0.31%. The ex-dividend date is Thursday, December 7th. C.R. Bard’s dividend payout ratio (DPR) is presently 13.70%.

COPYRIGHT VIOLATION NOTICE: “C.R. Bard, Inc. (BCR) Stake Decreased by Advisors Asset Management Inc.” was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright & trademark law. The original version of this piece of content can be read at https://www.watchlistnews.com/c-r-bard-inc-bcr-stake-decreased-by-advisors-asset-management-inc-2/1728856.html.

C.R. Bard Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Institutional Ownership by Quarter for C.R. Bard (NYSE:BCR)

Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.